Typhoid vaccination: the Asian experience.

Expert Rev Vaccines

Social Science Research and Institutional Development, International Vaccine Institute, San 4-8 Bongcheon-7-Dong, Kwanak-Gu, Seoul 151-818, Republic of Korea.

Published: July 2008

AI Article Synopsis

  • The WHO has updated its recommendations for using new-generation typhoid vaccines in areas where typhoid fever is common.
  • Countries are encouraged to create plans for implementing these recommendations and targeting vaccination efforts based on previous experiences.
  • The article reviews past vaccination programs in Thailand, China, Vietnam, and India, and highlights recent demonstration projects involving the Vi vaccine across five Asian countries.

Article Abstract

The WHO has recently issued updated recommendations for the programmatic use of new-generation typhoid vaccines in high-risk areas of countries where typhoid fever is still endemic. Countries have subsequently been instructed to discuss how these recommendations can be implemented and to develop plans for targeted typhoid vaccination. These plans can be informed by the experiences with typhoid vaccination that several Asian countries have had. This article reviews past and current typhoid vaccination programs that have taken place in Thailand (using the old whole-cell vaccine) and in China, Vietnam and India (using the new-generation injectable Vi polysaccharide vaccine). This review also describes recent typhoid Vi vaccine demonstration projects that were conducted in five Asian countries.

Download full-text PDF

Source
http://dx.doi.org/10.1586/14760584.7.5.547DOI Listing

Publication Analysis

Top Keywords

typhoid vaccination
16
vaccination asian
8
asian countries
8
typhoid
7
asian experience
4
experience issued
4
issued updated
4
updated recommendations
4
recommendations programmatic
4
programmatic new-generation
4

Similar Publications

The global public health risk posed by Salmonella Kentucky (S. Kentucky) is rising, particularly due to the dissemination of antimicrobial resistance genes in human and animal populations. This serovar, widespread in Africa, has emerged as a notable cause of non-typhoidal gastroenteritis in humans.

View Article and Find Full Text PDF

Pre-Harvest Non-Typhoidal Control Strategies in Commercial Layer Chickens.

Animals (Basel)

December 2024

Department of Comparative, Diagnostic, and Population Medicine, College of Veterinary Medicine, University of Florida, Gainesville, FL 32608, USA.

Non-typhoidal (NTS) infections in poultry, particularly in commercial-layer chickens, pose a critical risk to food safety and public health worldwide. NTS bacteria can remain undetected in poultry flocks, contaminating products and potentially leading to gastroenteritis in humans. This review examines pre-harvest control strategies for NTS in layer chickens, including biosecurity protocols, vaccinations, feed additives, genetic selection, and environmental management.

View Article and Find Full Text PDF

Fowl typhoid (FT) poses a significant threat to the poultry industry and can cause substantial economic losses, especially in developing regions. Caused by Salmonella Gallinarum (SG), vaccination can prevent FT. However, existing vaccines, like the SG9R strain, have limitations, including residual virulence and potential reversion of pathogenicity.

View Article and Find Full Text PDF

Introduction: Considerable evidence suggests a pathophysiological role of neuroinflammation in psychiatric disorders. Lumbar puncture and positron emission tomography (PET) show increased levels of inflammation in psychiatric disorders. However, the invasive nature of these techniques, as well as their expense, make them undesirable for routine use in patients.

View Article and Find Full Text PDF

Background: Enteric fever caused by Salmonella enterica serovars Typhi and Paratyphi A in addition to gastroenteritis and invasive disease, predominantly attributable to nontyphoidal Salmonella serovars Typhimurium and Enteritidis, are major causes of death and disability across the globe. A broad-spectrum vaccine that protects against disease caused by typhoidal and nontyphoidal serovars of Salmonella is not available for humans but would prevent a considerable burden of disease worldwide.

Methods: We previously developed a broad-spectrum vaccine for Gram-negative bacteria that is based on the inner core domain of detoxified Escherichia coli O111, Rc (J5) mutant lipooligosaccharide, a highly conserved antigen across Gram-negative bacteria, complexed with an outer membrane protein of group B Neisseria meningitidis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!